EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine

Angela T H Kwan, Ziji Guo, Felicia Ceban, Gia Han Le, Sabrina Wong, Kayla M Teopiz, Taeho Greg Rhee, Roger Ho, Joshua D Di Vincenzo, Sebastian Badulescu, Shakila Meshkat, Bing Cao und 6 weitere

Advances in Therapy · 2024

DOI: 10.1007/s12325-024-02826-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, 2024. Verfasst von Angela T H Kwan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Vortioxetine, Body Mass Index, Inflammation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: To date, there are no therapeutics that have gained regulatory approval by the United States Food and Drug Administration (FDA) for the treatment of post-COVID-19 condition (PCC), a debilitating condition characterized by cognitive impairment and mood symptoms. Additionally, persistent inflammation, metabolic dysfunction, and risks associated with an elevated body mass index (BMI) have been observed. Herein, we aimed to assess the efficacy of vortioxetine in improving depressive symptoms among individuals with PCC, as modulated by inflammation, metabolic dysfunction, and BMI. METHODS: In this post-hoc analysis, we present preliminary data obtained from an 8-week randomized, double-blind, placebo-controlled trial. Participants included adults aged 18 years and older residing in Canada who were experiencing symptoms of World Health Organization (WHO)-defined PCC. Recruitment began November 2021 and ended January 2023. Of the 200 participants enrolled, 147 were randomized (1:1) to receive vortioxetine (5-20 mg, n = 73) or placebo (n = 74) for daily treatment under double-blind conditions. The primary outcome measure was the change from baseline to endpoint in the 16-Item Quick Inventory of Depressive Symptomatology Self-Report Questionnaire (QIDS-SR-16). RESULTS: Our findings revealed significant effects for time (χ2 = 9.601, p = 0.002), treatment (χ2 = 9.135, p = 0.003), and the treatment × time × CRP × TG-HDL × BMI interaction (χ2 = 26.092, p < 0.001) on PCC-related depressive symptoms in the adjusted model. Moreover, the between-group analysis showed a significant improvement with vortioxetine at endpoint as compared to placebo (mean difference = - 5.41, SEM = 1.335, p < 0.001). CONCLUSION: Overall, vortioxetine significantly improved depressive symptoms among participants with PCC in the adjusted model. Notably, individuals with baseline markers of increased inflammation, metabolic disruption, and elevated BMI exhibited a more pronounced antidepressant effect at endpoint. TRIAL REGISTRATION NUMBER: NCT05047952 (ClinicalTrials.gov).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VortioxetineBody Mass IndexInflammationHumansMaleMiddle AgedDouble-Blind MethodFemaleAdultDepressionAgedCOVID-19SARS-CoV-2Antidepressive Agents

Stichwörter der Autor:innen

Body mass index (BMI)Depressive symptomsInflammationMetabolic dysfunctionPost-COVID-19 condition (PCC)Vortioxetine

Substanzen

VortioxetineAntidepressive Agents

Autor:innen und Institutionen

  • Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
  • Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
  • Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
  • Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.

ORCID-Profile: Roger S McIntyre

Zitieren

APA

Kwan, A. T. H., Guo, Z., Ceban, F., Le, G. H., Wong, S., Teopiz, K. M., Rhee, T. G., Ho, R., Di Vincenzo, J. D., Badulescu, S., Meshkat, S., Cao, B., Rosenblat, J. D., d'Andrea, G., Dev, D. A., Phan, L., Subramaniapillai, M., & McIntyre, R. S. (2024). Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine. Advances in Therapy. https://doi.org/10.1007/s12325-024-02826-9

Vancouver

Kwan ATH, Guo Z, Ceban F, Le GH, Wong S, Teopiz KM, et al. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine. Advances in Therapy. 2024. doi:10.1007/s12325-024-02826-9

BibTeX
@article{Kwan2024,
  author = {Kwan, Angela T H and Guo, Ziji and Ceban, Felicia and Le, Gia Han and Wong, Sabrina and Teopiz, Kayla M and Rhee, Taeho Greg and Ho, Roger and Di Vincenzo, Joshua D and Badulescu, Sebastian and Meshkat, Shakila and Cao, Bing and Rosenblat, Joshua D and d'Andrea, Giacomo and Dev, Donovan A and Phan, Lee and Subramaniapillai, Mehala and McIntyre, Roger S},
  title = {Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine},
  journal = {Advances in Therapy},
  year = {2024},
  doi = {10.1007/s12325-024-02826-9}
}
Kostenlos starten →